Compare Johnson & Johnson (JNJ) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.44 (market cap $296.92M). The key difference: Johnson & Johnson is far larger — about 2081.7× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Johnson & Johnson pays a 2.09% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| JNJ | YMAG | |
|---|---|---|
Market Cap | $618.09B | $296.92M |
Volume | 6,050,983 | 1,023,545 |
Sector | Health | Income / Options Overlay |
52-Week High | $278.43 | $15.68 |
52-Week Low | $186.00 | $10.76 |
Typical Hold Time | 129 Days | 62 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
YMAG trades at $11.44, down 0.44% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a consistent weekly dividend distribution schedule, with recent payouts ranging from $0.07 to $0.11 per share. Technical indicators show neutral oscillators but bearish momentum signals, with all support and resistance levels clustered around $11.
The outlook remains cautious due to the bearish technical setup and potential NAV volatility from underlying option strategies. Income-focused investors may find the distribution yield attractive, but price stability concerns persist given the concentrated support level and negative momentum indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
